Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent reform markup

Executive Summary

A markup of sweeping legislation to update the U.S. patent system for the first time in 50 years remains on the Senate Judiciary Committee's agenda for June 21 after being held over last week to allow further deliberation. A letter from several Republican committee members to Committee Chair Patrick Leahy, D-Vt., and Ranking Member Arlen Specter, R-Penn., says additional discussion among members, staff, the Patent and Trademark Office, the Department of Justice, and stakeholders is needed. The bill has moved rapidly through both houses of Congress, with contentious provisions including mandatory apportionment of damages, post-grant opposition, the granting of broad rule-making authority to PTO, and possible amendment of the Inequitable Conduct Doctrine (1"The Pink Sheet," June 11, 2007, p. 8)...

You may also be interested in...



PTO Wants Inequitable Conduct Doctrine Revised in Patent Reform Bill

With identical patent reform legislation moving rapidly through both houses of Congress, the U.S. Patent and Trademark Office is asking that the inequitable conduct doctrine be revised to encourage applicants to provide more and better information to examiners about their inventions

Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process

CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.

Faulty CDC COVID-19 Assays Leave Only 12 US Jurisdictions With Testing Ability, CDC Director Says

Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.

UsernamePublicRestriction

Register

PS048475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel